Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
utidelone + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Beijing Biostar Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Utidelone + gemcitabine is a combination chemotherapy regimen being investigated for the treatment of unresectable advanced pancreatic cancer. Utidelone is a genetically engineered modified analogue of epothilone that functions as a microtubule-stabilizing agent with a mechanism similar to taxanes but potentially overcoming taxane resistance. Gemcitabine is a well-established deoxycytidine analog that primarily inhibits DNA synthesis by competing with deoxycytidine triphosphate for incorporation into DNA, leading to chain termination and apoptotic cell death. This combination is currently in a Phase 2 clinical trial (NCT05795920) for advanced pancreatic cancer, aiming to evaluate its efficacy (PFS, OS, DOR) and safety.
- Other names
- Utidelone injection in combination with gemcitabine
02
Targets
DNAMicrotubuleRRM1RRM2CMPK1 (Deoxycytidylate kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on utidelone + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on utidelone + gemcitabine.